TarekMekhailMD

Medical Director of the Thoracic Oncology Program at the Florida Hospital Cancer Institute associate professor at the University of Central Florida

Join to view full profile

Dr. Mekhail is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Mekhail's full profile

Already have an account?

Office
2600 Westhall Ln
Maitland, FL 32751
Is this information wrong?

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 1999 - 2002
Cleveland Clinic FoundationResidency, Internal Medicine, 1995 - 1998
OtherClass of 1984
Cairo University School of MedicineClass of 1984

Certifications & Licensure

FL State Medical License 2008 - 2025
OH State Medical License 1998 - 2010
IA State Medical License 1997 - 1999
American Board of Internal Medicine Medical Oncology

Clinical Trials

Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors Start of enrollment: 2004 Aug 01
Completed
Phase 1
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Start of enrollment: 2009 Nov 01
Completed
Phase 3
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
Completed
Phase 3
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer Start of enrollment: 2015 Jul 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Random...
Yang, J., Han, B., De La Mora Jiménez, E., Lee, J., Koralewski, P., Karadurmus, N., Sugawara, S., Livi, L., Basappa, N., Quantin, X., Dudnik, J., Ortiz, D., Mekhail, T...> ;Journal of Thoracic Oncology. 2023 Dec 29
2 citations
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment forexon 20 insertion-positive non-small cell lung cancer.
James Chih-Hsin Yang, Caicun Zhou, Pasi A Jänne, Suresh S Ramalingam, Tae Min Kim, Gregory J Riely, Alexander I Spira, Zofia Piotrowska, Tarek Mekhail, Maria Rosario G...> ;Expert Review of Anticancer Therapy. 2023 Jan 1
5 citations
Mobocertinib (TAK-788) inExon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort.
Maria Rosario Garcia Campelo, Caicun Zhou, Suresh S Ramalingam, Huamao M Lin, Tae Min Kim, Gregory J Riely, Tarek Mekhail, Danny Nguyen, Erin Goodman, Minal Mehta, San...> ;Journal of Clinical Medicine. 2022 Dec 23
1 citations
GEMSTONE-302: "If you keep doing the same thing you get the same result".
Jieying Liu, Tarek Mekhail, Mark A Socinski, Guo, M.> ;Chinese Clinical Oncology. 2022 Dec 1
3 citations
A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors.
Jieying Liu, Ruoyu Miao, Zohaib Ahmed, James Yu, Jian Guan, Sarfraz Ahmad, Shuntai Zhou, Angela Grove, Manoucher Manoucheri, Mark A Socinski, Tarek Mekhail, Guo, M.> ;Journal of Immunotherapy. 2022 Sep 5
6 citations
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced-Positive NSCLC.
Dong-Wan Kim, Shirish Gadgeel, Scott N Gettinger, Gregory J Riely, Geoffrey R Oxnard, Tarek Mekhail, Peter Schmid, Afshin Dowlati, Rebecca S Heist, Antoinette J Woznia...> ;JTO Clinical and Research Reports. 2022 Aug 1
1 citations
Langerhans Cell Histiocytosis Associated With Renal Cell Carcinoma: Is it an Indolent Phenomenon or a More Ominous Pathologic Process?
Tien Anh N Tran, Tarek Mekhail> ;The American Journal of Surgical Pathology. 2022 Nov 1
68 citations
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
Edward S Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M Shagan, Sylvia Hu, Young Kwang Chae, Ticiana A Leal, Jonathan E Dowell, Michaela L Tsai, Christophe...> ;Nature Medicine. 2022 May 1
COVID-19 Outcomes in Stage IV Cancer Patients Receiving Immune Checkpoint Inhibitors.
Jieying Liu, Shuntai Zhou, James Yu, Zohaib Ahmed, Sarfraz Ahmad, Mark A Socinski, Tarek Mekhail, Vincent Hsu, Guo, M., Manoucheri, M.> ;SN Comprehensive Clinical Medicine. 2022 Jan 1
132 citations
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 O...
Caicun Zhou, Suresh S. Ramalingam, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, Maria Rosario Garcia Campelo, Enrique...> ;JAMA Oncology. 2021 Oct 14
Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy.
James B. Yu, Yuan Du, Tarek Mekhail, Mark A. Socinski, Chung-Che Chang> ;Clinical Lung Cancer. 2021 May 19
118 citations
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazh...> ;Cancer Discovery. 2021 Jul 1
2 citations
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study
Edward B. Garon, Katherine B. Winfree, Cliff Molife, Zhanglin Lin Cui, Edurne Arriola, Benjamin Levy, Tarek Mekhail, Maurice Pérol> ;Supportive Care in Cancer. 2021 Jan 1
Fat-Finding Mission: Primary Pleomorphic Liposarcoma of the Heart and Pericardium.
Jeremy R. Burt, Joseph Limback, Melanie Molina, Jorge Suarez, Tarek Mekhail, Naim Fanaian, Gilberto J. Aquino, Ismail Kabakus, Austin Weyant, Kurt Scherer> ;JACC. Case Reports. 2020 Aug 1
11 citations
Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Luwei Tao, Ruoyu Miao, Tarek Mekhail, Jingxin Sun, Lingbin Meng, Cheng Fang, Jian Guan, Akriti G Jain, Yuan Du, Amanda Allen, Brenda L. Rzeszutko, Mark A. Socinski, Ch...> ;Clinical Lung Cancer. 2021 Jul 1
23 citations
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squam...
David R. Spigel, Dianna Shipley, David M. Waterhouse, Suzanne F. Jones, Patrick J. Ward, Kent C. Shih, Brian Hemphill, Michael McCleod, Robert C. Whorf, Ray D. Page, J...> ;The Oncologist. 2019 Dec 1
905 citations
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-...
Howard Jack West, Michael McCleod, Maen A. Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans-Georg Kopp, Davey B. Daniel, Steven L. McCune, Tarek...> ;The Lancet. Oncology. 2019 Jul 1
10 citations
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.
Benjamin Levy, Luis Paz-Ares, Jaafar Bennouna, Enriqueta Felip, Delvys Rodriguez Abreu, Dolores Isla, Fabrice Barlesi, Olivier Molinier, Jeannick Madelaine, Clarisse A...> ;Clinical Lung Cancer. 2019 Jan 4
3 citations
High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer.
Nooshin Hashemi Sadraei, Yan Feng, Lingling Du, Pingfu Fu, Sulsal Haque, Afshin Dowlati, Jahnavi Gollamudi, Nathan A. Pennell, Tarek Mekhail, Stefanie Avril, Carol Far...> ;Lung Cancer. 2018 Dec 1
1717 citations
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott J. Antonia, A. Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, A. Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Cheol Cho, ...> ;The New England Journal of Medicine. 2018 Sep 25
228 citations
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer
Benjamin Solomon, Dong Wan Kim, Yi-Long Wu, Kazuhiko Nakagawa, Tarek Mekhail, Enriqueta Felip, Federico Cappuzzo, Jolanda Paolini, Tiziana Usari, Yiyun Tang, Keith D. ...> ;Journal of Clinical Oncology. 2018 May 16
3 citations
Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
David R. Spigel, John D. Hainsworth, Dianna Shipley, Tarek Mekhail, John D. Zubkus, David M. Waterhouse, Davey B. Daniel, Howard A. Burris, F. Anthony Greco> ;Lung Cancer. 2018 Mar 1
13 citations
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153
David M. Waterhouse, Leora Horn, Craig H. Reynolds, David R. Spigel, Jason C. Chandler, Tarek Mekhail, Mohamed K. Mohamed, Ben C. Creelan, Kenneth B. Blankstein, Petro...> ;Cancer Chemotherapy and Pharmacology. 2018 Feb 13
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia, S. J.,Villegas, A.,Daniel, D.,Vicente, D.,Murakami, S.,Hui, R.,Yokoi, T.,Chiappori, A.,Lee, K. H.,de Wit, M.,Cho, B. C.,Bourhaba, M.,Quantin, X.,Tokito, T.,Me...> ;N. Engl. J. Med.. 2017 Sep 09
5 citations
First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC)
David R. Spigel, Tarek Mekhail, David M. Waterhouse, Terence J. Hadley, Charles D. Webb, Howard A. Burris, John D. Hainsworth, F. Anthony Greco> ;Cancer Investigation. 2017 Aug 1
Join now to see all

Journal Articles

Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLC
David R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine